Ostarine may be the closest SARM to becoming accepted in medicine and it is presently in section II scientific trials. Like SARMs in general, MK-2866 targets androgen receptors over a selective basis and avoids generating the varieties of hazardous side effects connected with substances like testosterone, human growth hormone, or anabolic steroids,